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INTRODUCTION
Actively mediated cellular delivery of biomolecules (1) has garnered great interest as a strategy for delivering cancer chemotherapeutics (2) (3) (4) (5) . Conjugates of a drug and a macromolecular vehicle such as NLS 1 peptidic sequences (5) (6) (7) (8) , PEG carriers (9) and dendrimers (10) may have better cellular internalization than the drug alone, and in some cases, may produce passive accumulation of the drug in tumors by the EPR effect (11) . In addition, the therapeutic activity of these conjugates is associated to their capacity to release the drug at a specific subcellular target. Thus, the suitability of macromolecules as vehicles also extends to their propensity to deliver the drug to a predetermined intracellular location.
The marine alkaloid Lam-D (12-15) is a promising drug candidate due to its Topo I inhibition activity. Topoisomerases are nuclear enzymes crucial in cellular replication. They change the topology of DNA before and after the replication and transcription processes. Therefore, they are especially attractive targets for cancer therapy (16) (17) (18) (19) . Lam-D is limited by its insolubility in common solvent media, especially in water. Therefore, it has been used to investigate its conjugation to macromolecules. In the previous paper we have described the first generation of Lam D-bioconjugates based on PEG esters such as 1 (9) . In this paper we describe a second generation of Lam-D conjugates ( Figure 1 ) based on esterification with either a poly(ethylene glycol)-based dendrimer (in 2) or NLS oligopeptide sequences (in 3 and 4). The peptide NLS H-Pro-Pro-Lys-LysLys-Arg-Lys-Val-OH, which has been demonstrated (20) to shuttle compounds to the nucleus, was used in the present work.
The introduction of such oligomeric systems to Lam D demanded an integrated and robust synthetic scheme with a collection of suitable orthogonal protecting groups, in terms of selective removal and compatibility with the presence of other functional groups (21) . The same abbreviations were also used for the multiplicity of signals in 1 H-NMR, plus (m) multiplet, (bs) broad singlet, (bd) broad doublet. Spectra were referenced to appropriate residual solvent peaks (d 6 -acetone, d 6 -DMSO, d 4 -MeOH or CDCl 3 ). IR spectra were obtained on a Thermo
Nicolet FT-IR spectrometer. HRMS were performed on a Bruker Autoflex high resolution mass
spectrometer by Unidad de Espectrometría de Masas (Universidad de Santiago de Compostela) and by Servei d'Espectrometria de Masses (Universitat de Barcelona). Microwave-assisted reactions
were carried out in a CEM Discover microwave. The automatic syringe pump was used as specified for controlled addition of some reactants. Reversed phase analytical HPLC was performed on a Waters Alliance separation module 2695 using a Waters Xterra MS C 18 column (150 x 4.6 mm, 5 µm) and a Waters 996 PDA detector at 254 nm.
General Procedures:
A) General Method for Simultaneous Removal of TBDPSO and N-Boc.
HF (5 mL) at -196 ºC was poured over solid 11, 12 or 14 (0.05-0.08 mmol). The solution was stirred for 1 min and the solvent was immediately removed under vacuum at low temperature.
MeCN was added to the crude, and the deprotected compound was precipitated by addition of MTBE, cooling to 0 ºC and centrifugation (10 min, 2000 r.p.m.). The residue was dried in vacuo to
give the final Lam-D conjugates 1-3.
B) General Method for MOMO deprotection
Me 3 SiI (142 µL, 3.00 mmol) was added at r.t. to a solution of 10a, or 10b (1.00 mmol) in CH 2 The resin was then washed with DMF and CH 2 Cl 2 . The corresponding Fmoc-protected amino acid (5 equiv) was introduced using DIPCDI (310 µL, 5 equiv) and HOBt (305 mg, 5 equiv) as coupling agents. After 2h, the resin was washed with DMF and CH 2 Cl 2 , and the coupling was monitored using the Kaiser test. Re-couplings were done when needed. Boc-L-Pro-OH (430 mg, 5 equiv) was used as a last amino acid. The peptide was finally cleaved from the resin using 3% TFA in CH 2 Cl 2 ,
(5 x 1 min). Washes were collected in a flask containing 50 mL of water. 
11-Benzyl-4'-tert-butyldiphenylsilyl-3-methoxymethyl-Lam-D (22) (10).
A mixture of 9 (27) ( A colorimetric assay using SRB was adapted for quantitative measurement of cell growth and viability, following a previously described method (23) . 
4',11-Bis(tert-butyldiphenylsilyl)-3-methoxymethyl-Lam-D (10b

4'-tert-Butyldiphenylsilyl-Lam-D (22) (10c
4',11-Bis(tert-butyldiphenylsilyl)-3-[3-(2-(2-(2-(2-(2-(2-tertbutoxycarbonylaminoethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)propanoyl]Lam-D
(q); 27.3 (t); 28.4 (q); 29.4 (t); 29.7 (t); 35.3 (t); 37.0 (t); 38.4 (t); 39.5 (t); 54.5 (q); 55.4 (q); 55.
If Tz < T < C (growth inhibition), then the result is 100 × ([T − Tz]/[C − Tz]). If T < Tz (net cell death), then the result is 100 × ([T − Tz]/Tz).
After dose-curve generation, the results were expressed as GI 50 (the concentration that causes 50% cell growth inhibition, compared to control cultures). 
General Treatments for
Synthesis of Protected Lamellarins 5 and 6:
The protecting groups OiPr/OBn used in earlier strategies (9) required harsh deprotection conditions incompatible with the synthesis of more complex Lam-D conjugates such as 4. 2 The previously described lamellarin 9 (26, 27) , for which three different and orthogonal protecting groups were employed (MOM, Bn and TBDPS), was used as the precursor to Lam derivatives 5 and 6 3 (Scheme As a side note, compounds 10a and 10c are privileged synthetic intermediates for the construction of additional mono-, and di-conjugates at positions 11-OH, and 3,11-OHs of Lam-D, respectively.
Synthesis of poly(ethylene glycol)-based dendrimer 7
PEG-based dendrimer 7 was synthesized by coupling 1-(tertbutyloxycarbonylamino)-4,7,10-trioxa-13-tridecanamine to monobenzyl-protected diethylenetriamine pentaacetic acid with PyBOP and DIPEA. The tetracarboxylic moiety derivative was prepared from an orthogonally protected DTPA derivative (one benzyl and four tert-butyl protecting groups). The tBu groups were eliminated using 4.0 M HCl in dioxane, and then the benzyl group was eliminated by hydrogenolysis with Pd/C to render dendrimer 7 (29) .
Synthesis of the peptide NLS 8
The protected peptide 8 was synthesized on chlorotrityl resin following standard Fmoc/tBu solidphase chemistry, with 20% piperidine-DMF for the deprotection steps, and DIPCDI and HOBt as coupling reagents.
N-α-Fmoc-N-ω,N-ω'-bis-tert-butoxycarbonyl-L-arginine was used for the synthesis of the NLS
peptide sequence. Attempts to use Fmoc-N-ω-Pbf-L-arginine, resulted in harsher deprotection conditions and complex reaction crudes. The last amino acid used was Boc-L-Pro-OH (as the desired building block had to be completely protected). The peptide was cleaved from the resin using 3% TFA in CH 2 Cl 2 , and after solvent evaporation, it was lyophilized.
Esterification and Synthesis of Conjugates 1-4
To test the efficacy of the protecting scheme, the synthesis of bioconjugate 1 was repeated using the following strategy (21) . An ester bond between 5 and BocNH-CH 2 (CH 2 OCH 2 ) 6 CH 2 COOH was formed using EDC·HCl with a catalytic amount of DMAP to afford compound 11 (Figure 1 ) in quantitative yield. Compound 11 was considered a good model for the deprotection assays, because it contains the critical protecting groups and the ester functional group. Hence, it was used for the optimization of procedures and to test the success of the deprotection steps. Initial assays of sequential TBAF-TFA, two-step deprotection led to complex crude products. Furthermore, purification on SiO 2 gave low yields of 1. The best results were obtained via simultaneous deprotection of both groups, using liquid HF at low temperature. Highly pure final product was obtained from the reaction crude by precipitation with MTBE. Notwithstanding, the scope of the reaction was limited to small amounts of starting material. 4 Compound 1 was synthesized in 84% overall yield from its precursor 5. This is a major improvement over previous OiPr/OBn strategies (45% yield, from 4',11-diisopropyl-Lam-D) (9).
Formation of an ester bond between 5 and 7 (29) afforded compound 12 ( Fig. 1 ) in 26% yield, using EDC·HCl with a catalytic amount of PS solid supported DMAP in CH 2 Cl 2 . Deprotection of compound 12 using HF provided 2 in 36% yield.
Ester bond formation between 8 and protected lamellarin 5 or 6 using EDC·HCl was unsuccessful.
The inaccessibility of the carboxylic acid in the N-Boc protected oligopeptide sequence 8, or steric hindrance of the free phenolic group in Lam-D building blocks 5 and 6, may have been decisive to the lack of reaction. Various attempts at ester bond formation between 8 and the scaffold 5 were also unsuccessful. 5 Therefore, taking advantage of the relatively easy amide bond formation (i.e. compared to ester bonds), an N-Boc-Gly-OH spacer was introduced at position 3 of 5 (affording 13 in 89% yield, Fig. 2 ) for subsequent amide bond formation with 8. N-Boc deprotection of 13 with 40% TFA followed by reaction with 8 in EDC·HCl, HOBt, and DIPEA as base, gave 14 ( Fig. 1,   58% yield). Deprotection of 14 with HF under standard conditions afforded the NLS peptidic conjugate 3 in 38% yield.
The NLS conjugate at position 4' of Lam-D could not be formed using the same conditions employed for ester bond formation between 6 and 8. 6, 7 Instead, pre-activation of 8 with TCFH (30) and NEt 3 , followed by the addition of a solution of 6 and DMAP were required, affording 15 ( Fig. 1 ) in 45% yield (relative to 40% transformation of 6). Elimination of the nine Boc protecting groups with 40% TFA in CH 2 Cl 2 gave compound 4 in 17% yield.
The ester bond of compound 3, which has a double Gly spacer, is more susceptible to nucleophilic attack by nucleophiles from the medium than that of compound 4, which has a single Gly spacer.
Thus, the final conjugate 3 (derived from 14) was water labile. The rapid degradation of 3 made biological tests with this compound impossible. FACS flow cytometry was used to measure cellular uptake quantification (9) . The results are shown in Table 2 As described, GFP-Topo I was located in the nucleus (25) in all cell types (Fig.3, positive control) .
Conjugate 4, carrying the NLS signal, was localized to the nucleus in HT-29 and A-549 cells (Fig.   3, j1, j2, k1 and k2) , suggesting that its higher activity could correlate to subcellular co-localization with its target, Topo I.
Interestingly, Lam-D and 1 showed both higher activity and greater nuclear localization in MDA-MB-231 cells than 4 did (Fig. 3, f1 , f2, i1 and i2) N,N,N',N',N"-pentaacetic acid; EDC·HCl, N-(3-dimethylaminopropyl) 3 The ester bonds of the protected Lam-D conjugates were labile; hence, to avoid problems with hydrolysis, we minimized the deprotection steps after condensation. 4 The yield for the deprotection was 84% working on a 20-30 mg scale. However, the procedure could not be scaled up. The stability 1 was studied in DMEM supplemented with 10% FBS and 100 units/mL penicillin and streptomycin at 37 °C. HPLC analysis indicates 97% of Lam-D liberation after 360 min of incubation. 5 Esterification of 5 was tested with EDC·HCl, TCFH or N,N,N',N'-tetramethylchloroformamidyl chloride as activating agents. 6 N-Cbz-Gly-OH was anchored to 6 in quantitative yield. However, further Cbz deprotection could not be performed without concomitant hydrolysis of the conjugate ester bond. 7 Other coupling reagents as EDC·HCl, DIPCDI, TFFH, PyBOP with HOAt, and MSNT with NMI failed in ester bond formation. 8 Compound 3 quickly hydrolyzes and liberates Lam-D into the medium, even on the time scale of an HPLC analysis. --- 
DISCUSSION
